Safety of ninety-minute daratumumab infusion.
Jeffrey LombardiMathieu BoulinMadeline DevauxAmélie CransacPauline PistreCorinne PernotAlexandre PayssotIngrid LafonDenis CaillotPauline GueneauPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
From the third infusion, we found that a rapid administration of daratumumab (90 vs 210 minutes) was well tolerated and safe. It would be interesting to test this regimen from the second infusion.